Organogenesis Holdings Inc
ORGO
NASDAQ
Biotechnology
$1.79
USD
+0.03 (+1.70%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $230.97M
Volume 547.6K
Revenue
$514.70M
TTM
+12.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$2.72M
TTM
+117.1%
YoY
Operating Cash Flow
$30.75M
TTM
+593.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 86.7 | 101.0 | 150.9 | 225.6 | 37.2 |
YoY Growth | -21.2% | -22.4% | +31.0% | +78.1% | -57.1% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 86.7 | 101.0 | 150.9 | 225.6 | 37.2 |
Selling, General & Administrative | 72.5 | 73.8 | 79.7 | 100.2 | 65.2 |
Other Operating Expenses | 30.3 | 29.4 | 37.2 | 51.9 | 25.8 |
Total Operating Expenses | 113.4 | 113.6 | 130.1 | 162.3 | 106.1 |
Operating Income | -26.7 | -12.6 | 20.7 | 63.3 | -68.9 |
EBITDA | -15.9 | -6.3 | 26.5 | 70.1 | -59.0 |
Other Income / Expense | 0.0 | 0.1 | 0.0 | -0.1 | 0.0 |
Total Other Income / Expense | 1.0 | 0.7 | 0.4 | 0.1 | 0.4 |
Income Before Income Taxes | -25.8 | -11.8 | 21.2 | 63.4 | -68.5 |
Income Taxes | -6.9 | -2.4 | -0.4 | 19.7 | -15.3 |
Net Income | -18.8 | -9.4 | 21.6 | 43.7 | -53.2 |
Consolidated Net Income / Loss | -18.8 | -9.4 | 21.6 | 43.7 | -53.2 |
Net Income Attributable to Common Shareholders | -18.8 | -12.2 | 14.5 | 35.1 | -53.2 |
Basic EPS | -$0.17 | -$0.10 | $0.11 | $0.28 | -$0.44 |
Diluted EPS | -$0.17 | -$0.10 | $0.11 | $0.26 | -$0.44 |
Basic Shares Outstanding | 126.3M | 126.9M | 126.9M | 126.9M | 127.8M |
Diluted Shares Outstanding | 126.3M | 126.9M | 130.8M | 137.0M | 127.8M |